Overview of Eltrombopag
Eltrombopag is an oral non-peptide thrombopoietin receptor agonist (TPO-RA). It increases platelet production by activating the thrombopoietin receptor and promoting the proliferation and differentiation of bone marrow megakaryocytes. It is primarily indicated for the treatment of adult and pediatric patients (12 years of age and older) with chronic immune thrombocytopenia (ITP) who have an inadequate response to therapies such as corticosteroids or intravenous immunoglobulin.
Drug Interactions
Drugs containing calcium, iron, or aluminum (e.g., antacids, dairy products): May significantly reduce the absorption of eltrombopag. Administration should be separated by at least 4 hours.
Strong CYP3A4 inducers/inhibitors (e.g., rifampicin, ketoconazole): May affect plasma drug concentrations, requiring dose adjustment.
Anticoagulant/antiplatelet drugs (e.g., warfarin): May increase the risk of bleeding.
Special Population Precautions
Pregnant Women
Use only if the potential benefit justifies the potential risk to the fetus. Animal studies have demonstrated fetal toxicity.
Lactating Women
Breastfeeding should be avoided, as the drug may be excreted in human milk.
Patients with Hepatic Impairment
Patients with moderate to severe hepatic disease require a reduced starting dose (25 mg) and close monitoring.
Pediatric Patients
Dosing must be adjusted based on body weight; indicated for patients 1 year of age and older.
General Precautions
Monitoring Requirements
Platelet counts: Weekly monitoring during the initial treatment phase, then monthly once stable.
Liver function: Monitoring every 2 weeks.
Management of Missed Doses
If a dose is missed, take the usual dose at the next scheduled time. Do not double the dose to make up for the missed dose.
Discontinuation Principles
Dosing should be tapered gradually. Abrupt discontinuation may cause a sudden drop in platelet counts.
Important Reminder
As a targeted therapeutic agent, eltrombopag must be used under the guidance of a physician to balance efficacy and potential risks.
Note: The above information is a simplified version for patient reference. For complete drug information, please refer to the full prescribing information of this product. Patients are advised to consult a qualified physician before use and should not self-medicate.
